Showing 19,021 - 19,040 results of 30,943 for search '(( 50 ((((ppm decrease) OR (mean decrease))) OR (a decrease)) ) OR ( 2 step decrease ))', query time: 1.06s Refine Results
  1. 19021

    Supplementary Material for: Anatomical, functional, and prognostic results of vitrectomy in epiretinal membranes secondary to retinal vein occlusions by Chung Y.-R. (20312844)

    Published 2024
    “…Anatomically, the mean preoperative CMT was 501 ± 168 μm, decreasing to 348 ± 108 μm at month 24 (p=0.008). …”
  2. 19022

    DataSheet1_Effects of pharmacogenomics-guided treatment on medication adherence and the antidepressant switching rate in major depressive disorder.docx by Chaoli Chen (20359785)

    Published 2024
    “…Background<p>In the treatment of depression, medication plays a crucial role. However, insufficient patient adherence to medication often results in unsatisfactory treatment outcomes, increasing both the recurrence and rehospitalization rates of depression, and consequently imposing a greater economic burden on the healthcare system.…”
  3. 19023

    Coarse-grained model leads to collective behavior. by Giovanna De Palo (476510)

    Published 2017
    “…The peak in susceptibility becomes higher the larger the number of cells, and NN distances decrease accordingly. Profiles in the inset were smoothed with a moving average filter spanning ten points. …”
  4. 19024
  5. 19025
  6. 19026
  7. 19027
  8. 19028
  9. 19029
  10. 19030
  11. 19031
  12. 19032
  13. 19033
  14. 19034
  15. 19035

    Data_Sheet_1_SWL-1 Reverses Fluconazole Resistance in Candida albicans by Regulating the Glycolytic Pathway.doc by Xiao-Ning Li (2008540)

    Published 2020
    “…In this study, we show that SWL-1 reverses resistance to fluconazole in C. albicans when delivered in combination, with a sharp decrease in the IC<sub>50</sub> of fluconazole from >200 to 3.74 ± 0.25 μg/ml, and also reverses the fluconazole resistance of C. albicans in vitro, with IC<sub>50</sub> from >200 to 5.3 ± 0.3 μg/ml. …”
  16. 19036

    An Integrated Disease/Pharmacokinetic/Pharmacodynamic Model Suggests Improved Interleukin-21 Regimens Validated Prospectively for Mouse Solid Cancers by Moran Elishmereni (203218)

    Published 2011
    “…Simulations of the verified model surfaced important therapeutic insights: (1) Fractionating the standard daily regimen (50 µg/dose) into a twice daily schedule (25 µg/dose) is advantageous, yielding a significantly lower tumor mass (45% decrease); (2) A low-dose (12 µg/day) regimen exerts a response similar to that obtained under the 50 µg/day treatment, suggestive of an equally efficacious dose with potentially reduced toxicity. …”
  17. 19037
  18. 19038
  19. 19039
  20. 19040